Abstract
Immune checkpoint inhibitors (ICIs) blocking programmed death receptor 1 or its ligand (anti-PD-1/PD-L1) are a burgeoning class of promising cancer treatments. However, not all patients respond to these treatments. Although studies have suggested potential biomarkers to predict patients likely to respond to treatment, no consensus biomarker has been identified. Here, 95 peer-reviewed studies representing 18,978 subjects across 15 cancer types were meta-analyzed to determine biomarkers that best predicted ICI response within and across cancers. Performance was assessed using the sensitivity, specificity, area under the receiver operating characteristic curve, and others. Across all cancers, multimodal biomarkers and tumor mutational burden discriminated ICI response better than PD-L1 immunohistochemistry assays (IHC) (P=.04) with sensitivities of 0.57 and 0.70 and specificities of 0.76 and 0.53, respectively. Marginal improvements were also observed for nascent microbiome biomarkers compared to IHC (P=.06). Current ICI biomarker performances indicate that additional research is needed to develop highly accurate and precise biomarkers for widespread clinical adoption.
Competing Interest Statement
D.M.R. has stock and other ownership interests in Interpares Biomedicine. He has served in a consultant and advisory role for Pharmazam and Clariifi. He has received research funding from Novo Nordisk and has intellectual property related to the detection of liver cancer. H.L.M. has stock and other ownership interests in Cancer Genetics, Interpares Biomedicine, Clariifi, and serves as a consultant or advisory role for Gentris, Cancer Genetics, Saladax Biomedical, National Institutes of Health/National Cancer Institute, Admera Health, eviCore healthcare, Pharmazam, VieCure.
Funding Statement
D.M.R. and A.M. were supported in part by the Clinical and Translational Science Collaborative of Cleveland, (KL2TR002547) from the National Center for Advancing Translational Sciences (NCATS) component of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All of the data was publically available from peer reviewed papers and no IRB approval was required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Arshiya Mariam: mariama{at}ccf.org, Suneel Kamath: kamaths{at}ccf.org, Kimberly Schveder: kaschveder{at}gmail.com, Howard L. McLeod: hmcleod1965{at}gmail.com, Daniel M. Rotroff: rotrofd{at}ccf.org
Data Availability
All available data is provided in the Supplementary Material and through the publications referenced in the Supplementary Material.
